ADHD
Mental health medicine use in England reaches record high, NHSBSA report reveals
July 29, 2025Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …
ADHD coach and breathwork experts to run workshop for ADHD management
April 2, 2025Design & Creative, Freelancers ADHD, Neurology, healthcare, mental health, nervous system
ADHD coach John Harrington and breathwork facilitator Martin O’Toole will collaborate on ‘Breathwork for ADHD and Beyond’, a breathwork-orientated session …
NICE recommends digital tech for ADHD diagnosis in children and young people
July 16, 2024Medical Communications ADHD, Diagnostics, NICE
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …
Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children
August 2, 2023Research and Development ADHD, Hebrew University of Jerusalem, Psychiatry, brain stimulation, clinical trial, university of surrey
Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have found that non-invasive brain stimulation …
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
May 4, 2023Medical Communications ADHD, Akili, Neurology, PureTech Health, clinical trials
Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine company, has announced positive topline …
Expansion for first FDA-approved video game for ADHD treatment
July 23, 2021Medical Communications, Research and Development ADHD, FDA, US, digital therapeutics, technology
Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the addition of new gaming features …
FDA approves first new ADHD drug in a decade
April 6, 2021Manufacturing and Production ADHD, FDA, paediatric
The FDA have approved the first new drug for the treatment of attention deficit hyperactivity disorder (ADHD) in over a …
Aevi Genomic Medicine’s share price crashes 75% following ADHD trial failure
January 4, 2019Medical Communications, Research and Development ADHD, AEVI-001, Aevi Genomic Medicine, clinical trial failure, pharma
Aevi Genomic Medicine, a US drugmaker based outside of Philadelphia, has seen its share value plummet by 75% following the …
FDA rejects Sunovion’s ADHD drug dasotraline
September 3, 2018Sales and Marketing ADHD, FDA, dasotraline, drug, sunovion
The US Food and Drug Administration (FDA) have rejected American pharma firm Sunovion’s application to market dasotraline for the treatment …
Top Ten most popular articles on Pharmafile.com this week
August 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10
There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set …
Drugs should be preferred first-choice treatment for ADHD
August 8, 2018Research and Development ADHD, adults, amphetmines, children, prescription, ritalin
Ritalin and other amphetamines should be the preferred first-choice medications for the short-term treatment of ADHD, according to a study …
Akili’s video game digital treatment shows promise in ADHD, eyes FDA approval
December 4, 2017Research and Development, Sales and Marketing ADHD, AKL-T01, Akili, FDA, pharma, video game
Akili, an unlisted affiliate of London-listed PureTech Health, has unveiled top-line results of AKL-T01, a novel digital medicine which takes …
10 years later, Shire gains FDA approval for ADHD drug
June 21, 2017Research and Development, Sales and Marketing ADHD, Shire
Shire has revealed that the FDA has approved its long-acting and interestingly named ADHD drug, Mydayis. The approval comes more …
FDA approves first generic versions of Lilly’s ADHD drug
May 31, 2017Research and Development, Sales and Marketing ADHD, Apotex, Aurobindo, FDA, Glenmark, Teva
The FDA has given its approval for the commercialisation of the first-ever generic versions of Eli Lilly’s Strattera (atomoxetine) for …
Otsuka to acquire Neurovance in potential $250 million deal
March 6, 2017Sales and Marketing ADHD, Neurovance, Otsuka Pharmaceuticals
Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal …
Latest content
